Blocking glucose metabolism prevents development of metabolic syndrome

A novel approach to preventing diabetes and other expression of metabolic syndrome, which includes obesity, diabetes, and fatty liver disease, showed promising results in mouse model systems. The response by the liver to fasting has been present as a therapeutic pathway to boost hepatic and whole-host metabolism. However, the mechanisms underlying these metabolic consequences remain unclear. To help explain these mechanisms, investigators at Washington University School of Medicine (St. Louis, MO, USA) worked with various mouse models to evaluate the role of the enzyme epidermal-type lipoxygenase, eLOX3 (encoded by its gene, Aloxe3), as a potentially novel promotor of the therapeutic fasting response. Original Link: